Literature DB >> 31367046

The FNIH Biomarkers Consortium embraces the BEST.

Joseph P Menetski, Christopher P Austin, Linda S Brady, Guy Eakin, Chris Leptak, Abbey Meltzer, John A Wagner.   

Abstract

Keywords:  Drug discovery

Year:  2019        PMID： 31367046     DOI： 10.1038/d41573-019-00015-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  BIOMARKERS AND NEUROBEHAVIORAL DIAGNOSIS.

Authors:  Joshua B Ewen; William Z Potter; John A Sweeney
Journal:  Biomark Neuropsychiatry       Date:  2021-01-04

2.  Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Authors:  Gege Gui; Christopher S Hourigan
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

3.  Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.

Authors:  Arun J Sanyal; Sudha S Shankar; Roberto A Calle; Anthony E Samir; Claude B Sirlin; Sarah P Sherlock; Rohit Loomba; Kathryn J Fowler; Clayton A Dehn; Helen Heymann; Tania N Kamphaus
Journal:  Nat Med       Date:  2022-03       Impact factor: 87.241

Review 4.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

Review 5.  Opportunities and challenges in translational science.

Authors:  Christopher P Austin
Journal:  Clin Transl Sci       Date:  2021-07-08       Impact factor: 4.689
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.